GPX4

Across TCGA pan-cancer cohorts, GPX4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPX4 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPX4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPX4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where GPX4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.600	0.880	.001	29	view →
CCRCC	OS	Tertile	II,III,IV	0.871	0.488	.001	21	view →
GBM	OS	Tertile	All	0.357	0.834	<.001	15	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	12	view →
LUAD	DFS	Tertile	III,IV	0.315	0.913	.038	6	view →
LSCC	DFS	Median	II,III,IV	0.510	0.815	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPX4–HNSC (OS)

Open the HNSC breakdown →